How KIOXIA’s Memory-Centric AI Tackles Growing Challenges in Logistics

E-commerce keeps growing and with it, the number of products moving through warehouses every day. Items vary more than ever — different shapes, seasonal packaging, limited editions and constantly updated designs. At the same time, many logistics centers are dealing with labour shortages and rising pressure to automate.

But today’s image-recognition AI isn’t built for this level of change. Most systems rely on deep-learning models that need to be adjusted or retrained whenever new products appear. Every update — whether it’s a new item or a packaging change — adds extra time, energy use and operational cost. And for warehouses handling huge product catalogs, these retraining cycles can slow everything down.

KIOXIA, a company known for its memory and storage technologies, is working on a different approach. In a new collaboration with Tsubakimoto Chain and EAGLYS, the team has developed an AI-based image recognition system that is designed to adapt more easily as product lines grow and shift. The idea is to help logistics sites automatically identify items moving through their workflows without constantly reworking the core AI model.

At the center of the system is KIOXIA’s AiSAQ software paired with its Memory-Centric AI technology. Instead of retraining the model each time new products appear, the system stores new product data — images, labels and feature information — directly in high-capacity storage. This allows warehouses to add new items quickly without altering the original AI model.

Because storing more data can lead to longer search times, the system also indexes the stored product information and transfers the index into SSD storage. This makes it easier for the AI to retrieve relevant features fast, using a Retrieval-Augmented Generation–style method adapted for image recognition.

The collaboration will be showcased at the 2025 International Robot Exhibition in Tokyo. Visitors will see the system classify items in real time as they move along a conveyor, drawing on stored product features to identify them instantly. The demonstration aims to illustrate how logistics sites can handle continuously changing inventories with greater accuracy and reduced friction.

Overall, as logistics networks become increasingly busy and product lines evolve faster than ever, this memory-driven approach provides a practical way to keep automation adaptable and less fragile.

Keep Reading

Biotechnology

How AI Is Helping Decode the Tumor Microenvironment — and What It Means for Cancer Care

A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.

Ventureport Media Team

Updated

November 28, 2025 4:18 PM

Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH

Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.

Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.

Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.

The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.

“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.

The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.

Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.

The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.